Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Massimo Degan

Minimal Residual Disease (Mrd) in Non‐hodgkin Lymphomas: Inter‐laboratory Reproducibility on Marrow Samples With Very Low Levels of Disease Within the Fil (Fondazione Italiana Linfomi) MRD Network

Hematological Oncology

English

Related publications

A Clofarabine-Based Bridging Regimen in Patients With Relapsed ALL and Persistent Minimal Residual Disease (MRD)

Bone Marrow Transplantation

Transplantation

Hematology

2013

English

Preventing Relapse After Haematopoietic Stem Cell Transplantation for Acute Leukaemia: The Role of Post-Transplantation Minimal Residual Disease (MRD) Monitoring and MRD-directed Intervention

British Journal of Haematology

Hematology

2017

English

Minimal Residual Disease (Mrd) in Early Stage Follicular Lymphoma Can Predict Prognosis and Drive Rituximab Treatment After Radiotherapy

Hematological Oncology

English

Pet-Driven Radiotherapy in Patients With Low Risk Diffuse Large B-Cell Lymphoma (Dlbcl): The Dlcl10 Multicenter Phase 2 Trial by Fondazione Italiana Linfomi (Fil)

Hematological Oncology

English

Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)?

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2019

English

Statistics and Measurable Residual Disease (MRD) Testing: Uses and Abuses in Hematopoietic Cell Transplantation

Bone Marrow Transplantation

Transplantation

Hematology

2019

English

Novel Molecular Markers for Minimal Residual Disease (Mrd) Monitoring in Mantle Cell and Follicular Lymphoma: The Targeted Locus Amplification (Tla) NGS Strategy

Hematological Oncology

English

Measurable Residual Disease (MRD) Detection by Next Generation Sequencing (NGS) in Acute Lymphoblastic LEUKAEMIA (ALL)

English

Monitoring of Minimal Residual Disease (MRD) by Real-Time Quantitative Reverse Transcription PCR (RQ-RT-PCR) in Childhood Acute Myeloid Leukemia With AML1/ETO Rearrangement

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Massimo Degan

Minimal Residual Disease (Mrd) in Non‐hodgkin Lymphomas: Inter‐laboratory Reproducibility on Marrow Samples With Very Low Levels of Disease Within the Fil (Fondazione Italiana Linfomi) MRD Network

Related publications

A Clofarabine-Based Bridging Regimen in Patients With Relapsed ALL and Persistent Minimal Residual Disease (MRD)

Preventing Relapse After Haematopoietic Stem Cell Transplantation for Acute Leukaemia: The Role of Post-Transplantation Minimal Residual Disease (MRD) Monitoring and MRD-directed Intervention

Minimal Residual Disease (Mrd) in Early Stage Follicular Lymphoma Can Predict Prognosis and Drive Rituximab Treatment After Radiotherapy

Pet-Driven Radiotherapy in Patients With Low Risk Diffuse Large B-Cell Lymphoma (Dlbcl): The Dlcl10 Multicenter Phase 2 Trial by Fondazione Italiana Linfomi (Fil)

Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)?

Statistics and Measurable Residual Disease (MRD) Testing: Uses and Abuses in Hematopoietic Cell Transplantation

Novel Molecular Markers for Minimal Residual Disease (Mrd) Monitoring in Mantle Cell and Follicular Lymphoma: The Targeted Locus Amplification (Tla) NGS Strategy

Measurable Residual Disease (MRD) Detection by Next Generation Sequencing (NGS) in Acute Lymphoblastic LEUKAEMIA (ALL)

Monitoring of Minimal Residual Disease (MRD) by Real-Time Quantitative Reverse Transcription PCR (RQ-RT-PCR) in Childhood Acute Myeloid Leukemia With AML1/ETO Rearrangement